Aripiprazole in schizophrenia and schizoaffective disorder: A review

https://doi.org/10.1016/j.clinthera.2010.01.021Get rights and content

Abstract

Background: During the past decade, there has been some progress in the pharmacotherapy of schizophrenia and schizoaffective disorder. Current evidence supports the use of various second-generation, or atypical, antipsychotic medications, although few of these agents have been associated with long-term efficacy and tolerability. Aripiprazole is an atypical antipsychotic that has been found to improve positive and negative symptoms of schizophrenia with a favorable adverse-effect profile.

Objective: This article reviews the efficacy and tolerability of aripiprazole in the context of recommended management strategies for schizophrenia and schizoaffective disorder, and in comparison with first-generation and other second-generation antipsychotics.

Methods: A search of MEDLINE (1999–May 2009) was conducted for reports of short- and long-term clinical studies of atypical antipsychotics (including aripiprazole) and meta-analyses of randomized controlled trials comparing first- and second-generation antipsychotics (including aripiprazole) in the treatment of schizophrenia or schizoaffective disorder. The search terms were schizophrenia; schizoaffective disorder; pharmacogenetics; adverse effects; tardive dyskinesia AND atypical antipsychotics; aripiprazole; aripiprazole, schizophrenia, AND double-blind studies; and atypical antipsychotics AND adverse effects. The reference lists of identified articles were reviewed for additional relevant publications. Only full study publications were included.

Results: Based on the clinical evidence, including data from short-term (4–8 weeks) and long-term (26–52 weeks) randomized, double-blind clinical trials, aripiprazole has been associated with improvements in positive, negative, cognitive, and affective symptoms of schizophrenia and schizoaffective disorder. It has been associated with long-term (up to 52 weeks) symptom control in schizophrenia, as well as with efficacy in treatment-resistant schizophrenia. Common adverse effects associated with aripiprazole were nausea, insomnia, and agitation. These effects were usually transient. The evidence suggests that aripiprazole is unlikely to be associated with clinically significant weight gain or dyslipidemia, increased prolactin levels, or prolongation of the QTc interval. Compared with placebo, aripiprazole has been reported to have a relatively low potential for inducing metabolic syndrome.

Conclusions: Based on the evidence reviewed, aripiprazole monotherapy appears to be effective and well tolerated in treating the positive, negative, and cognitive symptoms of schizophrenia and schizoaffective disorder. It was associated with a low risk for the common adverse effects of antipsychotic therapy, including metabolic and endocrine alterations.

References (95)

  • JM Kane et al.

    The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials [published correction appears in Schizophr Res. 2009;107:334–335]

    Schizophr Res.

    (2008)
  • R Tandon et al.

    A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

    Schizophr Res.

    (2006)
  • WW Fleischhacker et al.

    A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

    Biol Psychiatry

    (2009)
  • JM Kane et al.

    Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks

    Schizophr Res.

    (2007)
  • R Kerwin et al.

    A multicentre, randomized, natu- ralistic, open-label study between aripiprazole and standard of care in the management of communitytreated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study

    Eur Psychiatry

    (2007)
  • ID Glick et al.

    The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials

    J Affect Disord.

    (2009)
  • KH Nuechterlein et al.

    Identification of separable cognitive factors in schizophrenia

    Schizophr Res.

    (2004)
  • E Stip et al.

    Cognitive discernible factors between schizophrenia and schizoaffective disorder

    Brain Cogn.

    (2005)
  • E Stip

    Cognition, schizophrenia and the effect of antipsychotics [in French]

    Encephale.

    (2006)
  • O Kampman et al.

    Indicators of medication compliance in first-episode psychosis

    Psychiatry Res.

    (2002)
  • JM Pierre et al.

    High-dose quetiapine in treatment refractory schizophrenia

    Schizophr Res.

    (2005)
  • U Halbreich et al.

    Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects

    Psychoneuroendocrinology.

    (2003)
  • JW Newcomer et al.

    Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine

    Schizophr Res.

    (2008)
  • DD Miller et al.

    Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from CATIE schizophrenia trial

    Schizophr Res.

    (2005)
  • A Caykoylu et al.

    Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy

    Prog Neuropsychopharmacol Biol Psychiatry.

    (2009)
  • S Saha et al.

    A systematic review of the prevalence of schizophrenia

    PLo S Med.

    (2005)
  • CR Bowie et al.

    Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms

    Am J Psychiatry.

    (2006)
  • W Gaebel et al.

    Schizophrenia practice guidelines: International survey and comparison

    Br J Psychiatry.

    (2005)
  • TA Moore et al.

    The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 Update

    J Clin Psychiatry.

    (2007)
  • E Stip

    Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics

    J Psychiatry Neurosci.

    (2000)
  • S Kasper et al.

    Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

    Int J Neuropsychopharmacol.

    (2003)
  • WT Carpenter

    Targeting schizophrenia research to patient outcomes

    Am J Psychiatry.

    (2006)
  • A Marneros

    Schizoaffective disorder: Clinical aspects, differential diagnosis, and treatment

    Curr Psychiatry Rep.

    (2003)
  • J Flynn et al.

    Pharmacologic treatment of hospitalized patients with schizoaffective disorder

    Psychiatr Serv.

    (2002)
  • JM Noel

    ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders

    Am J Health Syst Pharm.

    (2007)
  • E Holmes et al.

    Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia

    PLoS Med.

    (2006)
  • C Mihalopoulos et al.

    Is early intervention in psychosis cost-effective over the long term?

    Schizophr Bull.

    (2009)
  • AT Joyce et al.

    Impact of atypical antipsychotics on outcomes of care in schizophrenia

    Am J Manag Care.

    (2005)
  • A Ricciardi et al.

    Is early intervention in psychosis effective?

    Epidemiol Psichiatr Soc.

    (2008)
  • T Kikuchi et al.

    7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity

    J Pharmacol Exp Ther.

    (1995)
  • A Farah

    Atypicality of atypical antipsychotics

    Prim Care Companion J Clin Psychiatry.

    (2005)
  • JP Lindenmayer et al.

    Pharmacological treatment strategies for schizophrenia

    Expert Rev Neurother.

    (2004)
  • SM Stahl

    Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopa-mine receptors

    J Clin Psychiatry.

    (2001)
  • JA Gray et al.

    Molecular targets for treating cognitive dysfunction in schizophrenia

    Schizophr Bull.

    (2007)
  • LN Yatham et al.

    Atypical antipsychotics in bipolar depression: Potential mechanisms of action

    J Clin Psychiatry.

    (2005)
  • GK Thaker et al.

    Advances in schizophrenia

    Nat Med.

    (2001)
  • Cited by (93)

    • Comparable repetition blindness effect in patients with schizophrenia

      2023, Journal of Behavior Therapy and Experimental Psychiatry
    • Drugs for neuropsychiatric disorders

      2018, Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application
    • ROLE OF FUNCTIONAL FOODS IN PSYCHOTIC DISORDERS

      2024, Applications of Functional Foods in Disease Prevention
    View all citing articles on Scopus
    View full text